In terms of mortality, incidence and costs, respiratory diseases are second only to cardiovascular conditions. Globally, hundreds of millions of people suffer from chronic respiratory diseases. Climate change is probably responsible for several negative effects on our health, as described by WHO. In Europe and in the rest of the world, mortality from chronic respiratory and lung diseases is expected to increase in the future. IBSA offers a range of mucolytics and other products containing hyaluronic acid, indicated as an adjuvant treatment for several chronic conditions.
